Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Miller

Showing results (71-80 of 215) with videos related to

Pageof 22
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2017
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshopMaria Pia Amato, Tobias Derfuss, Bernard Hemmer, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|November 12, 2002
A magnetization transfer analysis of the thalamus in schizophreniaManny S Bagary, Jackie Foong, Michael Maier, et al.
Human Brain Mapping|January 3, 2013
Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSICarmen Tur, Claudia A M Wheeler-Kingshott, Daniel R Altmann, et al.
Archives of Neurology|March 14, 2007
Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosisFrancesco Manfredonia, Olga Ciccarelli, Zhaleh Khaleeli, et al.
Human Brain Mapping|February 14, 2012
Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five yearsBenedetta Bodini, Mara Cercignani, Zhaleh Khaleeli, et al.
Neuroimage|April 28, 2004
Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosisJaume Sastre-Garriga, Gordon T Ingle, Declan T Chard, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Neurobiology of Aging|December 18, 2010
Gray matter atrophy rate as a marker of disease progression in ADValerie M Anderson, Jonathan M Schott, Jonathan W Bartlett, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 24, 2014
Multiple sclerosis in New Zealand MāoriJohn F Pearson, Sridhar Alla, Glynnis Clarke, et al.
Brain : a Journal of Neurology|February 24, 2006
Selective magnetization transfer ratio decrease in the visual cortex following optic neuritisBertrand Audoin, Kryshani T M Fernando, Josephine K Swanton, et al.
Pageof 22

Showing results (71-80 of 215) with videos related to

Sort By:
Pageof 22
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2017
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshopMaria Pia Amato, Tobias Derfuss, Bernard Hemmer, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|November 12, 2002
A magnetization transfer analysis of the thalamus in schizophreniaManny S Bagary, Jackie Foong, Michael Maier, et al.
Human Brain Mapping|January 3, 2013
Spatial variability and changes of metabolite concentrations in the cortico-spinal tract in multiple sclerosis using coronal CSICarmen Tur, Claudia A M Wheeler-Kingshott, Daniel R Altmann, et al.
Archives of Neurology|March 14, 2007
Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosisFrancesco Manfredonia, Olga Ciccarelli, Zhaleh Khaleeli, et al.
Human Brain Mapping|February 14, 2012
Corpus callosum damage predicts disability progression and cognitive dysfunction in primary-progressive MS after five yearsBenedetta Bodini, Mara Cercignani, Zhaleh Khaleeli, et al.
Neuroimage|April 28, 2004
Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosisJaume Sastre-Garriga, Gordon T Ingle, Declan T Chard, et al.
BMJ (Clinical Research Ed.)|March 8, 2003
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosisJim Chilcott, Chris McCabe, Paul Tappenden, et al.
Neurobiology of Aging|December 18, 2010
Gray matter atrophy rate as a marker of disease progression in ADValerie M Anderson, Jonathan M Schott, Jonathan W Bartlett, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 24, 2014
Multiple sclerosis in New Zealand MāoriJohn F Pearson, Sridhar Alla, Glynnis Clarke, et al.
Brain : a Journal of Neurology|February 24, 2006
Selective magnetization transfer ratio decrease in the visual cortex following optic neuritisBertrand Audoin, Kryshani T M Fernando, Josephine K Swanton, et al.
Pageof 22